NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD
Overall ETON gets a fundamental rating of 4 out of 10. We evaluated ETON against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ETON have multiple concerns. ETON is not overvalued while it is showing excellent growth. This is an interesting combination.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -5.45% | ||
ROE | -18.74% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 58.49% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.23 | ||
Debt/FCF | N/A | ||
Altman-Z | 2.73 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.97 | ||
Quick Ratio | 1.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 10.02 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 7307.81 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
13.7
+0.09 (+0.66%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 10.02 | ||
P/S | 7.6 | ||
P/FCF | N/A | ||
P/OCF | 66.46 | ||
P/B | 15.03 | ||
P/tB | N/A | ||
EV/EBITDA | 7307.81 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -5.45% | ||
ROE | -18.74% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 58.49% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.23 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 576.77 | ||
Cap/Depr | 426.09% | ||
Cap/Sales | 16.83% | ||
Interest Coverage | N/A | ||
Cash Conversion | 10632.7% | ||
Profit Quality | N/A | ||
Current Ratio | 1.97 | ||
Quick Ratio | 1.43 | ||
Altman-Z | 2.73 |